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Introduction {#sec1}
============

Until recently, it was assumed that differentiation was mostly a unidirectional and irreversible route that cells undertake during lineage commitment. This dogma was rebutted by the groundbreaking discovery of Yamanaka and colleagues that the expression of four transcription factors (TFs) could reprogram mouse and human cells into a pluripotent stage ([@bib41; @bib42]). Subsequent studies have established that cellular-fate conversion is also obtained by direct transdifferentiation between two distinct lineages. Transdifferentiation is generally achieved by overexpressing lineage-instructive TFs, as demonstrated by the effective cell-fate switching of fibroblasts into neuronal, hepatocyte, and cardiomyocyte lineages ([@bib7; @bib13; @bib14; @bib24; @bib37; @bib45]).

The hematopoietic system relies on the existence of a rare population of hematopoietic stem cells (HSCs) that are able to self-renew and reconstitute the entire system by generating all hematopoietic lineages. In the clinic, transfusion of HSCs and terminally differentiated blood cells (erythrocytes, platelets, and granulocytes) is used to successfully treat blood genetic disorders and malignancies. However, a major restriction to the wider use of these treatments is the limited availability of cells from donors with adequate match. An alternative strategy for the generation of patient-specific hematopoietic cells would be to differentiate induced pluripotent stem cells (iPSCs) to HSCs. Unfortunately, so far, the development of robust methods to produce blood cells and, in particular, transplantable long-term HSCs has met with limited success ([@bib2; @bib39]). Therefore, direct reprogramming of patient-derived cells by transdifferentiation represents an attractive alternative strategy for the generation of transplantable blood cells.

Hematopoiesis is governed by the combined functions of numerous TFs, complicating attempts to establish simple approaches toward transdifferentiation into this lineage. This complexity is highlighted by knockout studies that identified multiple regulators of blood cell generation including SCL, RUNX1, ERG, and GATA2 ([@bib20; @bib26; @bib34; @bib44]). Genome-wide chromatin immunoprecipitation data indicated that these four factors, in conjunction with LMO2, LYL1, and FLI1, create a regulatory complex that mediates transcription of multiple genes in hematopoietic progenitor cells ([@bib46]). Each TF of this heptad has been shown to act at multiple stages of hematopoietic specification, maturation, and differentiation ([@bib19]). For example, SCL is required during the formation of hemogenic endothelium precursors from hemangioblast and mesoderm ([@bib17]). RUNX1 is critical for the emergence of hematopoietic progenitors and HSCs from hemogenic endothelium ([@bib5; @bib17]). ERG is required for the maintenance of fetal HSCs and also for the self-renewal and survival of adult HSCs ([@bib20; @bib43]). Synergistic, antagonistic, and sequential relationships among these TFs create complex regulatory landscapes that shape the hematopoietic identity ([@bib30]).

Previous studies have revealed an inherent plasticity of hematopoietic cells, as they are amenable to transdifferentiation and dedifferentiation. Recently, this approach has been remarkably employed for the generation of inducible HSCs (iHSCs) by reprogramming blood cells or endothelium ([@bib33; @bib36]). In both studies, cells capable of multilineage long-term engraftment were obtained by transient ectopic expression of TFs selectively expressed in HSPCs. Importantly, the successful generation of iHSCs required provision of a favorable niche for the maturation of the cells in the form of either the in vivo bone marrow environment or a vascular support mimicking the aorta-gonad-mesonephros (AGM) niche. However, reprogramming of differentiated blood cells might not be suitable for the generation of healthy transplantable cells for patients with blood malignancies or acquired genetic diseases ([@bib29]). In addition, it could prove very difficult to obtain enough endothelial cells from an adult patient to perform reprogramming. An approach more appropriate for this purpose, but also more challenging, would be to reprogram more developmentally distinct cell types, such as fibroblasts, into blood. In this context, it has been shown that the TFs PU.1 and cEBPα were capable of reprogramming fibroblasts into mature macrophage-like cells ([@bib8]). However, reprogramming of fibroblasts to more immature hematopoietic progenitors has so far remained challenging. The first attempt, reported in 2010, involved the ectopic expression of the pluripotency factor OCT4 in human fibroblasts ([@bib40]). Although OCT4-induced hematopoietic progenitors exhibited myeloid and erythroid potential, lymphoid potential and long-term in vivo engraftment capacity were not achieved. Moreover, the use of the pluripotent TF OCT4 also raises concerns about tumorigenicity, as partial reprogramming induced by OCT4 could mimic a neoplastic state ([@bib25]). More recently, the combinatorial expression of a limited set of hematopoietic TFs, including GATA2, GFI1b, ETV6, and c-FOS in fibroblasts, was shown to induce a hemogenic endothelial cell fate ([@bib28]). However, the reprogrammed cells subsequently displayed only minimal hematopoietic potential despite coculture with placental cells.

In this report, we establish that fibroblasts can be rapidly and robustly reprogrammed to hematopoietic progenitors. The ectopic expression of five hematopoietic TFs, functionally selected from a range of 19 regulators, reproducibly induced hematopoietic fate in adult and embryonic fibroblasts within 8 days. The reprogrammed progenitors exhibited multilineage clonogenic capacity in vitro. Genome-wide transcriptional analyses of the reprogrammed cells revealed that the generation of hematopoietic progenitors was preceded by a hemogenic endothelial stage.

Results {#sec2}
=======

Reprogramming of Fibroblasts to Hematopoietic Fate with a Pool of Hematopoietic TFs {#sec2.1}
-----------------------------------------------------------------------------------

The aim of the present study was to investigate whether the ectopic expression of specific hematopoietic TFs could result in a direct and rapid cell fate conversion to hematopoietic precursors. First, we carefully selected a set of 19 different hematopoietic TFs based on their expression and function during hematopoiesis ([Table S1](#app3){ref-type="sec"}). The expression of most of the selected TFs spans from the onset of blood development during ontogeny to the adult blood system ([@bib27]). Lentiviruses expressing each individual factor were prepared and a cocktail of all TFs was used to infect primary fibroblasts. As a source of starting material, we used either embryonic day 14.5 (E14.5) mouse embryonic fibroblasts (MEFs) or mouse adult ear skin fibroblasts (MAFs). Prior to infection, these cells were depleted of any CD41-, CD31-, c-KIT-, and CD45-positive cells to eliminate potential contamination by hematopoietic and endothelial cells ([Figure 1](#fig1){ref-type="fig"}A). Posttransduction, the infected cells were switched to a media supporting the growth of hematopoietic cells, and the appearance of colonies containing round cells was monitored daily. Starting from day 8, we observed in transduced MEFs and MAFs cultures, but not in untransduced control cells, the emergence of colonies of small round cells often associated with cobblestone-like areas ([Figure 1](#fig1){ref-type="fig"}B). These colonies continued to expand during the following weeks of culture.

The transduced cells were next tested by immunostaining for the acquisition of the hematopoietic cell-surface markers c-KIT and CD41, which are expressed on emerging blood cells during embryonic development ([@bib22; @bib23]), and for the expression of hematopoietic genes. Live staining at day 12 indicated that cells in emerging colonies were positive for CD41 expression ([Figure S1](#app3){ref-type="sec"}A). Flow cytometry (fluorescence-activated cell sorting \[FACS\]) analyses at day 21 confirmed the acquisition of CD41 and low levels of c-KIT expression by the transduced MEFs and MAFs ([Figure S1](#app3){ref-type="sec"}B). Gene expression analyses on 3-weeks-posttransduced cells clearly indicated the downregulation of the fibroblasts markers (*Acta2* and *Fbn1*) ([Figure 1](#fig1){ref-type="fig"}C). In contrast, the expression of genes associated with erythroid (embryonic *β-H1* and adult *β-major* hemoglobin), megakaryocytic (*Pf4*), and myeloid (*Itgam* and *Mpo*) lineages were markedly upregulated in these cultures ([Figure 1](#fig1){ref-type="fig"}C). The expression of both *β-H1* and *β-major* hemoglobin genes suggests the presence of both primitive and definitive erythroid cells in these cultures. Having demonstrated the induction of a hematopoietic gene signature, we next sought to determine whether the reprogrammed cells possessed functional hematopoietic clonogenic potential. Day 21 reprogrammed MEFs and MAFs, but not untransduced fibroblasts, generated hematopoietic colonies containing macrophage, erythroid, and granulocytic cells upon replating in clonogenic assays ([Figure 1](#fig1){ref-type="fig"}D). May-Grünwald Giemsa staining confirmed the presence of cells with erythroid, megakaryocytic, and myeloid morphologies in these colonies ([Figure 1](#fig1){ref-type="fig"}E). Collectively, these experiments established that both embryonic and adult fibroblasts could be reprogrammed to hematopoietic cells upon the ectopic expression of 19 hematopoietic TFs.

ERG, GATA2, LMO2, RUNX1c, and SCL Reprogram Fibroblasts to Blood {#sec2.2}
----------------------------------------------------------------

Our next aim was to define the minimal combination of TFs required for reprogramming to blood cells. By eliminating each TF individually from the pool, taking into account the redundancy among TFs, and reiteration, we established that a minimal set of five TFs (ERG, GATA2, LMO2, RUNX1c, and SCL) was able to robustly and reproducibly induce the generation of colonies of round cells in both adult and embryonic fibroblasts ([Figure 2](#fig2){ref-type="fig"}A, left; [Movie S1](#mmc2){ref-type="supplementary-material"}). The efficiency of reprogramming was consistently higher in MEFs than in MAFs ([Figure 2](#fig2){ref-type="fig"}A, right). Several other combinations of TFs could also induce the generation of hematopoietic colonies from MEFs, albeit with lower efficiencies. The combination of ERG, FLI1, GATA2, PU.1, and SCL or the triad of FLI1, GATA2, and SCL, which controls the specification of mammalian hematopoietic progenitors ([@bib31]), induced the generation of hematopoietic colonies in MEFs ([Figure S2](#app3){ref-type="sec"}A). However, as the combination of the five TFs efficiently and reproducibly reprogrammed both MEFs and MAFs, we selected this set for further experiments. FACS analyses of day 21 MEF and MAF transduced cultures confirmed the acquisition of the hematopoietic markers c-KIT, CD41, CD45, CD11b, and TER119 ([Figure 2](#fig2){ref-type="fig"}B). Clonogenic assays and cytospin analysis of day 21 reprogrammed cells confirmed that five-TF-transduced MEFs and MAFs exhibited erythroid and myeloid potential ([Figures 2](#fig2){ref-type="fig"}C and 2D). Finally, sorted CD45/CD11b double-positive cells were able to uptake red fluorescent latex beads, demonstrating their phagocytic capacity and functionality ([Figure 2](#fig2){ref-type="fig"}E).

We next set out to determine the specific requirement for each TF and therefore performed "*N* minus 1" experiments. In MAFs, SCL, LMO2, and RUNX1c were more important than ERG and GATA2 for the generation of hematopoietic colonies ([Figure S2](#app3){ref-type="sec"}B). In MEFs, SCL and LMO2 alone were sufficient, albeit at a lower efficiency, to generate hematopoietic colonies containing CD41-, CD45-, and c-KIT-positive cells ([Figure S2](#app3){ref-type="sec"}C); in contrast, no colonies were obtained with these two TFs in MAFs ([Figure S2](#app3){ref-type="sec"}C). To investigate if the hematopoietic phenotype of the reprogrammed cells was dependent on the sustained expression of the exogenous TFs, we performed quantitative RT-PCR (qRT-PCR) on day 4 and day 21 transduced MEFs with primers specific for exogenous transduced factors. These experiments demonstrated that the vector-driven transcription of all five TFs was silenced by day 21 ([Figure S2](#app3){ref-type="sec"}D). In contrast, vector integration of all five viruses was enriched upon the emergence and expansion of blood cells in these cultures ([Figure S2](#app3){ref-type="sec"}E). These results established the contribution of all five exogenous factors in the induction of the hematopoietic program. In addition, qRT-PCR specific for the endogenous genes indicated that expression of all five endogenous TFs was induced during reprogramming ([Figure S2](#app3){ref-type="sec"}F). Finally, to determine the growth factors and cytokines essential to reprogram fibroblasts, we performed "*N* minus 1" experiments with MEFs. We observed that interleukin-3 (IL-3) was absolutely critical for reprogramming ([Figure S2](#app3){ref-type="sec"}G), a finding consistent with its established role in the maintenance of hematopoietic progenitor cells. Collectively, our results indicate that the combination of ERG, GATA2, LMO2, RUNX1c, and SCL efficiently induces reprogramming of both embryonic and adult fibroblasts to blood.

Five-TF-Induced Reprogramming Generates Multipotent Progenitors {#sec2.3}
---------------------------------------------------------------

Both morphological analysis and cell-surface staining data suggested that a large fraction of day 21 reprogrammed hematopoietic cells were already mature and differentiated at this stage ([Figure 2](#fig2){ref-type="fig"}D). To investigate whether fibroblasts were reprogrammed through a transient hematopoietic progenitor stage, or transdifferentiated more directly to mature blood cells, we investigated the emergence of cells positive for hematopoietic precursor markers by FACS. We observed from day 10 onward a sudden rise in the frequency of c-KIT/CD41 double-positive cells followed by a similar rise in the emergence of CD45^+^ cells from day 12 ([Figure 3](#fig3){ref-type="fig"}A). Time-course replating of transduced MEF cultures in semisolid colony assays indicated a transient peak of clonogenic potential around day 12--15 ([Figure 3](#fig3){ref-type="fig"}B), which correlated with higher frequencies of c-KIT^+^ cells. A similar gradual increase in the number of c-KIT^+^ cells and peak of clonogenic potential was observed in transduced MAF cultures ([Figures S3](#app3){ref-type="sec"}A and S3B). Confirming the relationship between c-KIT acquisition and clonogenic potential, c-KIT^+^ cells displayed a higher clonogenic potential than c-KIT^−^ cells (data not shown). When c-KIT^+^ sorted cells were cultured in conditions that specifically support the growth of erythroid and myeloid cells, CD71/TER119 and CD11b/GR1 double-positive cells were respectively detected ([Figure 3](#fig3){ref-type="fig"}C). When evaluated in clonogenic replating assays, c-KIT^+^ cells generated colonies containing erythroid, megakaryocytic, and myeloid cells ([Figure 3](#fig3){ref-type="fig"}D). Relatively similar genomic integration levels of the five vectors were observed between erythroid TER119 and myeloid CD11b-positive cells ([Figure S3](#app3){ref-type="sec"}C). This observation suggests that both lineages have similar TF requirements for their generation and/or that they are generated through a common progenitor. Collectively, these results indicate that hematopoietic progenitors with myeloid, erythroid, and megakaryocytic potential are generated early during reprogramming.

To investigate the presence of multipotential progenitors, we evaluated the frequency of clonogenic precursors in the c-KIT^+^ fraction, containing all hematopoietic progenitor cells, including the most immature precursors. Limiting dilution analyses indicated that 1 in 20 c-KIT^+^ cells generated colonies when cultured on OP-9 stromal cells (data not shown). To investigate if c-KIT^+^ cells have multilineage clonal ability, single day 12 fibroblast-derived c-KIT^+^ cells were sorted onto OP-9 stromal cells and amplified for 2 weeks ([Figure 3](#fig3){ref-type="fig"}E). FACS and May-Grünwald Giemsa staining indicated the presence of erythroid, myeloid, and megakaryocytic cells in cultures initiated with a single c-KIT^+^ cell ([Figure 3](#fig3){ref-type="fig"}E). These results suggest that fibroblasts are reprogrammed to the blood program, at least in part, through multipotential hematopoietic progenitor cells.

To further determine if hematopoietic stem cells might be generated during reprogramming, we performed FACS analyses for the SLAM markers on day 12 reprogrammed cells that were amplified on OP9-DL1. LIN^−^c-KIT^+^SCA1^+^ (LSK) cells were detected in these cultures, and some of the LSK cells were CD48^−^CD150^+^, indicating the presence of phenotypic HSCs ([Figure S3](#app3){ref-type="sec"}D). Additionally, we also observed phenotypic HSCs identified by the combination EPCR^+^CD48^−^CD45^+^CD150^+^ ([Figure S4](#app3){ref-type="sec"}A). We next investigated if these reprogrammed cells have the capacity to engraft mice in vivo. For this, we established E14.5 MEFs from a transgenic mouse carrying the GFP reporter cDNA under the control of the pan-hematopoietic *AI467606* gene promoter ([@bib10]). We amplified day 12 reprogrammed cells on OP9-DL1 stromal cells for 2 weeks. At this stage, GFP^+^ cells, characterizing both progenitors and differentiated cells, or c-KIT^+^ cells, including the most immature progenitors, were sorted and injected into two irradiated immunocompromised mice per each group. After 2 weeks, we monitored the presence of GFP^+^ cells in the peripheral blood and detected short-term engraftment of both injected populations ([Figures 3](#fig3){ref-type="fig"}F and [S4](#app3){ref-type="sec"}B). Engrafted cells were mostly TER119^+^ erythroid cells ([Figure S4](#app3){ref-type="sec"}B). However, 8 weeks postinjection, we could not detect engraftment greater than 1% in peripheral blood (data not shown). Collectively, these results suggest that the five-TF-mediated reprogrammed cells have short-term engraftment capacity and that further optimization of the culture conditions or TF composition will be necessary to obtain long-term engraftment capacity.

Loss of p53 Increases the Efficiency of Reprogramming to Blood {#sec2.4}
--------------------------------------------------------------

The loss of p53 or p16/p19 function has been shown to dramatically improve the efficiency of reprogramming to the pluripotent state ([@bib12; @bib18]). We therefore investigated whether similarly deletion of these genes improved reprogramming of fibroblasts to blood. Following transduction with the five TFs, we observed significantly higher numbers of hematopoietic colonies generated by p53 and p16/p19-null MEFs than by wild-type MEFs ([Figure 4](#fig4){ref-type="fig"}A). These colonies emerged as early as 5 days after transduction, and scoring was performed on day 6, as their excessive proliferation precluded individual counting at later time points. Reprogramming of p53^−/−^ MEFs resulted in the emergence of hematopoietic progenitors with multilineage potential ([Figures 4](#fig4){ref-type="fig"}B and 4C). Also, loss of p53 or p16/p19 function significantly increased the frequency of TER119^+^ erythroid cells generated by reprogrammed cells ([Figure 4](#fig4){ref-type="fig"}D). Cells with mature megakaryocytic morphologies that stained positive for acetylcholinesterase activity were also more readily observed with p53^−/−^ reprogrammed MEFs ([Figure 4](#fig4){ref-type="fig"}E). To evaluate the lymphoid potential of p53^−/−^ reprogrammed cells, sorted c-KIT^+^ cells were cultured and passaged on OP-9 or OP9-DL1 stromal cells in culture conditions supporting B or T cell growth, respectively. Cells positive for the B cell markers B220/CD19 emerged and proliferated during the culture of reprogrammed p53^−/−^ MEFs ([Figure 4](#fig4){ref-type="fig"}Fi). A fraction of B220/CD19 double-positive reprogrammed p53^−/−^ cells were also positive for immunoglobulin M expression ([Figure 4](#fig4){ref-type="fig"}Fi). The B cell identity of sorted B220/CD19-positive cells was further confirmed by detection of V(D)J chain rearrangements by PCR and sequencing ([Figure 4](#fig4){ref-type="fig"}Fii). Similarly, some reprogrammed p53^−/−^ MEFs cells cultured on OP9-DL1 stromal cells acquired the expression of the early T cell marker CD25 and displayed T cell receptor rearrangements, confirming early T lymphoid commitment ([Figures 4](#fig4){ref-type="fig"}Gi and 4Gii). Collectively, these results demonstrate that p53^−/−^ MEFs are more efficiently reprogrammed to hematopoietic progenitors with erythroid, myeloid, megakaryocyte, and B and T lymphoid lineage potential than wild-type MEFs, indicating that P53 expression is a barrier for reprogramming to blood.

Reprogramming to Blood Occurs via an Intermediate Endothelial Stage {#sec2.5}
-------------------------------------------------------------------

We next investigated the molecular events and cellular processes leading to the reprogramming of fibroblasts to blood progenitors. The rapid emergence of hematopoietic colonies suggested that the reprogramming did not involve a pluripotent stem cell stage with subsequent differentiation into blood cells. Accordingly, the expression of pluripotent markers (*Oct4*, *Sox2*, and *Nanog*) was not detected during the course of reprogramming ([Figure 5](#fig5){ref-type="fig"}A). The detection of embryonic hemoglobin *β-H1* expression in reprogrammed cells ([Figure 1](#fig1){ref-type="fig"}C) suggested that the reprogramming process might recapitulate to some extent embryonic hematopoiesis. During embryonic hematopoiesis, mesodermal hemangioblast precursors generate primitive as well as definitive blood cells through an intermediate hemogenic endothelium stage. We evaluated by PCR whether the reprogramming of fibroblasts to blood process was associated with any of these distinct embryonic steps. Although we did not detect any expression of the *Brachyury* mesodermal marker (data not shown), we clearly observed a peak of endothelial gene expression (*Cdh5*, *Tie2*, and *Icam1*; *Pecam1* and *Vwf*) early in reprogramming ([Figures 5](#fig5){ref-type="fig"}B and 5C). In contrast, hematopoietic genes (*Itga2b*, *Mpo*, and *Pu.1*) showed a delayed but steady increase in expression from day 12 to day 21 ([Figure 5](#fig5){ref-type="fig"}D). Live staining for vascular endothelial cadherin (CDH5) performed on day 5 cultures confirmed the early emergence of clusters of CDH5^+^ endothelial cells ([Figure 5](#fig5){ref-type="fig"}E). To determine if these endothelial cells corresponded to hemogenic endothelium that gives rise to differentiated blood cells, we sorted CDH5^+^ and CDH5^−^ cells from c-KIT-depleted day 6 transduced MEFs to eliminate any potential hematopoietic precursors. The cells were then cultured in conditions that support the transition to hematopoietic progenitors before seeding them in clonogenic assays. As shown in [Figure 5](#fig5){ref-type="fig"}F, CDH5^+^, but not CDH5^−^, cells generated hematopoietic colonies, demonstrating their hemogenic potential. In addition, these c-KIT^−^/CDH5^+^ endothelial cells acquired the hematopoietic markers CD41, CD45, and c-KIT upon culture on OP9 ([Figure S5](#app3){ref-type="sec"}A). We concluded from these results that reprogramming of fibroblasts to blood cells proceeds through an intermediate hemogenic endothelial cellular stage.

Transcriptome Analyses on Reprogrammed Cells {#sec2.6}
--------------------------------------------

To define the global changes in gene expression driving reprogramming of fibroblasts to hematopoietic lineages, we performed exon array analyses on biological replicates of untreated MEFs (Un), day 8 sorted CDH5^+^ cells, and day 12 sorted c-KIT^+^ cells. We identified 868 significantly (5% false discovery rate \[FDR\]) differentially expressed genes (DEGs). Principal component analyses based on these DEGs confirmed the correlation between replicates and the differences between cells at the three stages of reprogramming ([Figure S6](#app3){ref-type="sec"}A). We then performed hierarchical clustering on DEGs and observed three main clusters ([Figure 6](#fig6){ref-type="fig"}A). The first cluster mostly contained genes that were gradually downregulated from untransduced MEFs to CDH5^+^ and then to c-KIT^+^ populations and were associated with adhesion and muscular development ([Figure 6](#fig6){ref-type="fig"}A; [Table S2](#app3){ref-type="sec"}). This cluster included fibroblast-specific genes (*Acta2*, *Actg2*, *Col2A*, *Col4a1*, *Col5a1*, and *Fgf3*) that were silenced during reprogramming. The second cluster encompassed genes that were upregulated in CDH5^+^ cells but then downregulated in c-KIT^+^ cells. These genes were mainly of endothelial nature and associated with blood vessel development and cell-cell adhesion ([Figure 6](#fig6){ref-type="fig"}A; [Table S2](#app3){ref-type="sec"}). The third cluster included genes that were moderately expressed in CDH5^+^ cells, highly expressed in c-KIT^+^ populations, and associated with ontology terms such as development of the hematopoietic program, leukocyte migration, chemotaxis, and response to infection/wounding ontology terms ([Figure 6](#fig6){ref-type="fig"}A; [Table S2](#app3){ref-type="sec"}). Pathway analyses with DAVID confirmed that hematopoietic pathways were already activated in the CDH5^+^ fraction, a finding consistent with a hemogenic endothelium identity ([Table S2](#app3){ref-type="sec"}). To further confirm this transient upregulation of the endothelial program, we performed gene set enrichment analyses (GSEA) with endothelial-specific genes. As expected, genes upregulated between MEFs and CDH5^+^ cells, and downregulated between CDH5^+^ and c-KIT^+^ cells, were positively correlated with an endothelial gene signature ([Figure 6](#fig6){ref-type="fig"}B). These analyses also indicated an enrichment for genes specifically upregulated in CDH5^+^ cells for early hematopoietic progenitors signature, whereas c-KIT^+^-specific genes were more closely associated with late or differentiated hematopoietic progenitor cells ([Figures 6](#fig6){ref-type="fig"}C and [S6](#app3){ref-type="sec"}B). Finally, we investigated to which extent our reprogrammed cells were similar to HSCs by comparing our transcriptome signature with previously published data sets from different HSC populations isolated from diverse hematopoietic tissues ([@bib21]). We observed that CDH5^+^ cells clustered with AGM, placental, and yolk sac HSCs that have been classified as specifying HSCs. Interestingly, c-KIT^+^ cells clustered more closely with definitive HSCs from fetal liver, bone marrow, and embryonic stem cell (ESC)-derived HSCs ([Figure 6](#fig6){ref-type="fig"}D). Collectively, our transcriptome analyses further support the concept that reprogramming to hematopoietic progenitors proceeds through a hemogenic endothelium intermediate. This CDH5^+^ cell population, while displaying clear evidence of its endothelial nature, also expressed hematopoietic genes and displayed similarity with emerging HSCs and early progenitors, whereas the later c-KIT^+^ population was more closely associated with hematopoietic progenitors.

Discussion {#sec3}
==========

In this study, we establish that fibroblasts can be robustly reprogrammed to hematopoietic cell fate by concomitant ectopic expression of the hematopoietic TFs ERG, GATA2, LMO2, RUNX1c, and SCL. These five TFs have been shown to interact and act at diverse stages of the hematopoietic program; i.e., from the onset of its development to the more established adult hematopoietic hierarchy ([@bib46]). In particular, SCL, GATA2, and FLI1, a distinct but related-to-ERG ETS factor, form an interconnected regulatory triad that is activated during specification of HSCs ([@bib31]). Once established, this circuit is self-maintained, providing the newly specified progenitors with a memory of their stemness in a similar fashion as OCT4, SOX2, and NANOG in pluripotent ESCs ([@bib4]). Furthermore, ERG, when expressed along with HOXA9 and RORA, has also been shown to confer multilineage potential to myeloid-restricted precursors ([@bib6]). The transcription factor SCL and its binding partners are implicated in the induction of the hematopoietic program in mesoderm and the generation of hemogenic endothelium ([@bib11; @bib16]). Finally, RUNX1 physically interacts with SCL, ERG, and GATA2 and is critical for the transition from hemogenic endothelium to hematopoietic stem and progenitor cells (HSPCs) ([@bib5; @bib17; @bib46]). Furthermore, enforced expression of the isoform RUNX1a enhances hematopoietic lineage commitment from human ESCs and iPSCs ([@bib32]). The close functional association among these five TFs during normal HSPCs generation could explain why we functionally identified them as the best combination of TFs to robustly induce a complex hematopoietic program in differentiated fibroblasts. Interestingly we also demonstrated that SCL and LMO2 are sufficient to induce hematopoietic fate in embryonic but not adult fibroblasts. This finding raises the interesting prospect that a limited set of small-molecule modulators could reinforce reprogramming or even circumvent the need for viral transduction.

We observed that the generation of blood precursors by the ectopic expression of our set of five TFs is a very fast process. The first morphological signs of cellfate switching were observed by day 5 followed by the emergence and proliferation of c-KIT^+^ progenitors by 8 days. These cells exhibited a wide range of differentiation potential with robust generation of granulocytes and functional macrophages and, to a lower extent, erythrocytes and megakaryocytes. Furthermore, using fibroblasts with a p53^−/−^ background broadened the range and increased the frequency of the generated lineages. In addition to larger pool of erythrocytes and megakaryocytes, we were able to generate B and T cells at different developmental stages. The results obtained with p53^−/−^ MEFs provide a proof of principle that our combination of five TFs is suitable for reprogramming to all major blood lineages. The addition of small-molecule modulators that transiently increase epigenetic plasticity or briefly inhibit p53 or p16 might further extend the range and frequency of lineages generated from wild-type fibroblasts. In contrast, a permanent inactivation of p53 might not be desirable given the requirement for p53 to limit aberrant self-renewal ([@bib47]).

Establishing methods for transdifferentiation of nonhematopoietic cells to blood lineage remains challenging due to significant epigenetic barriers to overcome and the need to induce and maintain complex regulatory networks in these cells. So far, there are only two reports describing transdifferentiation of fibroblasts to blood progenitors. In the first study, hematopoietic progenitors with multilineage potential were generated by overexpression of a single pluripotency factor, OCT4, in a hematopoietic-supportive culture environment ([@bib40]). The use of a pluripotent TF, however, raises some concerns about tumorigenicity. In the second report, Pereira et al. demonstrated that ectopic expression of c-FOS, ETV6, GATA2, and GFI1b reprogrammed fibroblasts to hemogenic endothelial cells, which upon further coculture with placental cells generated myeloid cells, albeit with a low efficiency (around 10 colonies for 100,000 starting MEFs) ([@bib28]). Although reprogramming by c-FOS, ETV6, GATA2, and GFI1b, as well as our combination of five TFs, seems to transit through a similar hemogenic endothelium intermediate stage, the efficiency and kinetics are quite different. While these authors identified a hemogenic endothelium population emerging by day 35 of reprogramming, our results indicate the emergence of an endothelial population as early as day 5. We detected c-KIT^+^ functional hematopoietic progenitors with multilineage potential as early as 8 days after transduction, whereas Pereira et al. obtained only limited myeloid potential after more than 6 weeks of culture. Collectively, these results indicate that our combination of TFs induce the rapid generation of a multipotent blood progenitors with better efficiency than previously reported.

Several lines of evidence suggest that the reprogramming of fibroblasts to blood cells recapitulates the embryonic process of blood development. CD41, the first hematopoietic marker we detected at the surface of transitioning reprogrammed cells, is widely expressed on the earliest blood progenitors generated during ontogeny ([Figure S1](#app3){ref-type="sec"}A) ([@bib9; @bib22; @bib23; @bib35]). The detection of primitive erythrocytes expressing the embryonic βH1-hemoglobin also suggests that these TFs are inducing early developmental steps. Moreover, the presence of a transient hemogenic endothelium population resembles the endothelial-to-hematopoietic transition that takes place during blood development in the yolk sac or dorsal aorta ([@bib3; @bib15; @bib16; @bib48]). Finally, the detection of phenotypic HSCs, as well as the gene expression profile clustering of the CDH5^+^ cell population with specifying HSC cell populations, further supports the hypothesis that the reprogramming mimics early hematopoietic development ([Figures 6](#fig6){ref-type="fig"}D, [S3](#app3){ref-type="sec"}D, and [S4](#app3){ref-type="sec"}A). The fact that we are recapitulating the normal embryonic program of blood development suggests that it may be only due to the limitations of the in vitro cultures that we cannot functionally identify an emerging HSC population. The reports by the Rossi and Rafii's laboratories emphasize the requirement for a supportive niche to obtain engraftable populations upon reprogramming of blood or endothelial cells ([@bib33; @bib36]). Providing a similar in vivo bone marrow or in vitro vascular support might greatly improve the repopulation potential of cells generated from fibroblasts and therefore will be a major direction for further research.

In conclusion, we provide a report of efficient and rapid reprogramming of fibroblasts to blood progenitors with a limited set of hematopoietic TFs. Fibroblasts represent an accessible and safe starting cell population for reprogramming. Despite many remaining questions, the approach reported here holds a huge promise and should be further optimized and developed for its safe use in clinical settings.

Experimental Procedures {#sec4}
=======================

MEF and MAF Preparation {#sec4.1}
-----------------------

E14.5 MEFs were isolated as described previously ([@bib38]). MAFs were isolated from the ears of 2- to 6-month-old mice by collagenase digestion. Passage 0 fibroblasts were cultured until confluent and frozen. Before infection, MEFs and MAFs were depleted of cells positive for the hematopoietic/endothelial markers CD41, CD31, c-KIT, and CD45.

Lentivirus Transduction, Colony-Forming Unit Assay, and Reaggregation {#sec4.2}
---------------------------------------------------------------------

MEFs/MAFs (15,000) were seeded on a gelatin-coated 12-well plate, and after 24 hr viral transductions were carried out in the presence of 10 μg/ml diethylaminoethyl dextran. After 4 hr of transduction, the cultures were placed in hematopoietic media (1× Iscove's modified Dulbecco's medium supplemented with plasma-derived serum \[PDS; Antech\], 10% protein-free hybridoma medium \[PFM; GIBCO\], 0.5 mM ascorbic acid, 4.5 × 10^−4^ M MTG, 2 mM L-glutamine, 80 mg/ml transferrin, 1% c-KIT ligand, 1% IL-3, 1% granulocyte-macrophage colony-stimulating factor, 1% thrombopoietin conditioned media, 4 U/ml erythropoietin \[Ortho-Biotech\], 10 ng/ml macrophage colony-stimulating factor, 10 ng/ml IL-6, 5 ng/ml IL-11 \[all from R&D Systems\], and 50 μg/ml penicillin-streptomycin). Colony-forming unit (cfu) assays were performed as described previously ([@bib38]). To evaluate the presence of hemogenic endothelium, CDH5^+^ and CDH5^−^ cells were sorted from day 6 cultures that were depleted for c-KIT^+^ cells to avoid hematopoietic contamination. A total of 20,000 sorted cells were mixed with 100,000 irradiated OP9 cells, cultured overnight in hanging-drop cultures, and then on Durapore filter (Millipore) for another 4 days. Single-cell suspensions obtained following dissociation with collagenase/dispase solution were assayed in cfu assays.

Transplantation Assay {#sec4.3}
---------------------

E14.5 MEFs for transplantation experiments were obtained from a reporter mouse line with GFP expression under the control of *AI467606* promoter ([@bib10]). Day 12 transduced cells were harvested and further expanded for 2 weeks on OP-DL1 stroma cells in hematopoietic medium. GFP- or c-KIT-positive cells were sorted and intravenously injected in 6- to 8-week-old lethally irradiated NSG mice (n = 2). The level of engraftment was determined by GFP expression in peripheral blood. All animal work was performed under regulations set out by the Home Office Legislation under the 1986 United Kingdom Animal Scientific Procedures Act.

Affymetrix Analyses and Integration of Data Sets {#sec4.4}
------------------------------------------------

Global gene expression analyses were done using the Mouse Exon 1.0 ST arrays. The R/Bioconductor package LIMMA was used to identify genes that were differentially expressed among the three conditions. Differentially expressed genes were obtained with significant p value and at 5% FDR. The distance weighted discrimination ([@bib1]) method for cross-platform normalization was done for our transcriptome data sets along with McKinney data sets ([@bib21]). Hierarchical clustering was performed using the complete linkage.
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![Screen for Hematopoiesis-Inducing TFs\
(A) Schematic representation of experimental strategy. Murine embryonic fibroblasts (MEFs) were prepared from day 14.5 embryos, and murine adult fibroblasts (MAFs) were prepared from adult ear skin. Cells expressing the surface markers CD31, CD41, c-KIT, and CD45 were excluded from the starting populations. Sorted cells were transduced with a cocktail of all TFs. After 21 days of culture, cells were analyzed for hematopoietic cell-surface markers, clonogenic capacity, and cellular and nuclear morphology.\
(B) Bright-field images of untransduced and all TFs transduced MEFs and MAFs at day 12.\
(C) Relative gene expression levels of indicated genes with respect to β-actin in untransduced (Un), all-TF-transduced MEFs, control bone marrow (BM), and control E10.5 aorta-gonad-mesonephros (AGM) region cells. Data presented are representative of one out of three independent experiments performed in triplicate (n = 3; mean ± SD).\
(D) Number of hematopoietic colonies generated by 50,000 all-TF-transduced day 21 harvested MEFs/MAFs (left). Mean ± SEM from two independent experiments performed in triplicates is shown (n = 2). Representative bright-field images of the different types of colonies observed (right).\
(E) Cellular morphology of day 21 transduced MEFs/MAFs and ESC-derived hematopoietic cells. Arrowheads depict indicated morphologies.\
Gr, granulocyte; M, macrophage; P, progenitor; E, erythrocyte; Mk, megakaryocyte, Scale bars represent 50 μm. Asterisks indicate significant differences (Student's t test; ^∗∗∗^p \< 0.0005).](gr1){#fig1}

![Five TFs Induce Reprogramming to Blood\
(A) Bright-field images of five TFs transduced MEFs/MAFs at day 12 (left). Number of round cell colonies observed per 15,000 transduced MEFs/MAFs (right, n = 5, mean ± SEM).\
(B) FACS analysis of untransduced and five-TF-transduced MEFs and MAFs at day 21.\
(C) Number of hematopoietic colonies generated by 50,000 five-TF-transduced day 21 harvested MEFs/MAFs (left, n = 4, mean ± SEM). Representative bright-field images of the different types of colonies observed (right).\
(D) Cellular morphology analyses of day 21 transduced MEFs/MAFs and control bone marrow (BM) derived cells. Arrowheads depict indicated morphology. Gr, granulocyte; M, macrophage; P, progenitor; E, erythrocyte; Mk, megakaryocyte. Scale bars represent 50 μm.\
(E) Phagocytic capacity of CD45/CD11b double-positive cells. Asterisks indicate significant differences (Student's t test; ^∗∗^p \< 0.01).](gr2){#fig2}

![Multilineage Potential of Five-TF-Reprogrammed Cells\
(A) Acquisition of hematopoietic cell surface markers during the course of reprogramming. Average percentages of cells expressing CD41, c-KIT, and CD45 are represented at indicated intervals after five-TF transduction of MEFs (n = 2, performed in duplicate; mean ± SD).\
(B) Number of hematopoietic colonies generated by 50,000 reprogrammed MEFs from day 7 to day 21 (n = 2, performed in duplicate; mean ± SEM).\
(C and D) Multilineage potential of five TFs reprogrammed day 12 sorted c-KIT^+^ cells. (C) Sorted c-KIT^+^ cells were cultured under erythroid and myeloid culture conditions for 1 week and FACS analyzed for cell-surface markers. (D) Morphology of colonies and cells generated by sorted c-KIT^+^ cells.\
(E) FACS and cellular morphology of cells derived from day 12 sorted single c-KIT^+^ cell expanded on OP9 for 2 weeks (n = 3).\
(F) Percentage reconstitution in peripheral blood determined by detection of donor-derived GFP^+^ cells after 2 weeks of transplantation in two individual mice per group (1 and 2) either with GFP^+^ or c-KIT^+^ reprogrammed cells.](gr3){#fig3}

![Reprogramming p53-Null MEFs\
(A) Number of round cell colonies observed at day 6 per 15,000 transduced WT, p53^−/−^, and p16/p19^−/−^ MEFs (n = 4; mean ± SEM).\
(B) Number and types of hematopoietic colonies generated by 50,000 five-TF-reprogrammed p53^−/−^ MEFs harvested from day 6 to 15. Data presented are mean ± SEM of triplicates in a representative experiment (n = 2).\
(C) Morphology of colonies and cells obtained from five-TF-transduced day 12 sorted c-KIT^+^ p53^−/−^ MEFs.\
(D) Average percentage of TER119 and CD11b/GR1 double-positive cells generated by day 12 sorted c-KIT^+^ cells from WT, p53^−/−^, and p16/p19^−/−^ transduced MEFs (n = 3; mean ± SEM).\
(E) Acetylcholinesterase staining of megakaryocytes derived from bone marrow or generated by day 12 sorted c-KIT^+^ reprogrammed p53^−/−^ MEFs.\
(Fi) FACS analysis of c-KIT^+^ sorted reprogrammed p53^−/−^ MEFs after expansion on OP9 in lymphoid medium.\
(Fii) BCR rearrangements detection in B220^+^/CD19^+^ sorted reprogrammed p53^−/−^ MEFs, control untransduced MEFs (Un) and spleen cells.\
(Gi) FACS analysis of c-KIT^+^ sorted reprogrammed p53^−/−^ MEFs after expansion on OP9-DL1 in lymphoid medium.\
(Gii) TCR rearrangement detection in sorted CD25^+^ reprogrammed p53^−/−^ MEFs, control untransduced MEFs (Un) and thymus cells.\
Asterisk(s) represents statistical significance (Student's t test; ^∗^p \< 0.05, ^∗∗^p \< 0.01).](gr4){#fig4}

![Fibroblasts Are Reprogrammed to Blood via an Intermediate Hemogenic Endothelial Stage\
(A--D) Relative gene expression levels of pluripotent (A), endothelial (B), endothelial/ hematopoietic (C), and hematopoietic (D) markers with respect to β-actin at indicated days after five-TF transduction and in control bone marrow (BM) and aorta-gonad-mesonephros (AGM) region cells. Data presented are mean ± SD from one representative experiment (n = 3).\
(E) Immunostaining of day 5 five-TF-transduced MEFs for CDH5 (red) and DAPI (blue).\
(F) Schematic strategy to determine hemogenic potential of CDH5^−^cKIT^−^ and CDH5^+^cKIT^−^ five-TF-transduced cells (top). Number, type, and morphology of hematopoietic colonies generated by sorted cells reaggregated with irradiated OP9 stromal cells.\
Data presented are mean ± SEM of triplicates of a representative experiment (n = 2). Scale bars represent 50 μm.](gr5){#fig5}

![Global Transcriptome Analyses of Reprogrammed Cells\
Day 8 CDH5^+^ (CDH5-positive) and day 12 c-KIT^+^ (c-KIT-positive) flow-sorted cells were compared to untreated (Un) MEFs in duplicate by mouse Affymetrix exon arrays.\
(A) Hierarchical clustering of differentially expressed genes (DEGs) among untreated MEFs, day 8 sorted CDH5^+^, and day 12 sorted c-KIT^+^ cells. Genes specific to specified cell types are shown on the right.\
(B) Gene set enrichment analysis (GSEA) for endothelial gene signature in untreated, CDH5^+^, and c-KIT^+^ transcriptomes.\
(C) Normalized enrichment score (NES) values obtained after performing GSEA for indicated gene sets comparing CDH5^+^ and c-KIT^+^ transcriptome data sets.\
(D) Unsupervised hierarchical clustering of DEGs in our transcriptome data sets along with expression in HSCs from different hematopoietic organs ([@bib21]).](gr6){#fig6}
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